The BTG2 mutation facilitates p65’s entry into the nucleus and activates NF-κB signaling, which impacts the molecular mechanism underlying DLBCL’s malignant phenotype. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.